Skip to main content
. 2017 Jan 12;22(2):30439. doi: 10.2807/1560-7917.ES.2017.22.2.30439

Table 4. Genotypic drug susceptibility testing results, cluster of multidrug-resistant tuberculosis, Austria, Romania and Germany, 2010 to 2014 (n = 13).

ID H R R Z E E E Eth/Pt Eth/Pt Ami S SM PAS FQ
Rv1908c Rv0667 Rv0667 Rv2043c Rv3795 Rv3795 Rv3795 Rv3854c Rv3854c MTB000019 Rv3919c Rv0682 Rv2764c Rv0007
katG [26] rpoB [8,25] rpoB [8,25] pncA [27] embB [8,28] embB [8,28] embB [8,28] ethA [29] ethA [29] Rrs [8] gidB [25] rpsL [25] thyA [30] gyrA [8]
I S315T a WT S450L a A146V a WT WT D1024N b WT Ins 802 ag b WT Q125_ b WT R222Cb A288Db
II S315T a WT S450L a A146V a M306I a WT WT Ins 1391 a b WT WT Q125_ b WT WT WT
III S315T a WT S450L a A146V a WT G406Sa D1024N b WT WT WT Q125_ b WT WT WT
IV S315T a WT S450L a A146V a M306I a WT WT Ins 1391 a b WT WT Q125_ b WT WT WT
V S315T a WT S450L a A146V a M306I a WT WT Ins 1391 a b WT WT Q125_ b WT WT WT
VI S315T a WT S450L a A146V a WT G406S a D1024N b WT WT 1401 A -> G a Q125_ b WT WT WT
VII S315T a WT S450L a A146V a WT G406S a D1024N b WT WT WT Q125_ b WT WT WT
VIII S315T a WT WT A146V a WT WT WT WT WT WT Q125_ b WT WT WT
IX S315T a WT S450L a A146V a M306I a WT D1024N b WT WT WT Q125_ b WT WT WT
X S315T a WT S450L a A146V a M306I a WT WT Ins 1391 a b WT 1401 A- > G a Q125_ b WT WT WT
XI S315T a WT S450L a A146V a WT G406S a D1024N b WT WT WT Q125_ b WT WT WT
XII S315T a T400A a S450L a WT WT WT WT WT WT WT WT K43R1 WT WT
XIII S315T a T400A a S450L a WT WT WT WT WT WT WT WT K43R1 WT WT

Ami: aminoglycoside; E: ethambutol; Eth: ethionamide; FQ: fluroquinolones; ID: unique patient identifier; H: isoniazid; PAS: para-aminosalicylic acid; Pt: protionamide; R: rifampicin; S: streptomycin; Z: pyrazinamide; WT: wild type.

a resistance mediating mutation.

b resistance associated variant.